ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients
Open Access
- 5 May 2021
- journal article
- review article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 191 (7), 1154-1164
- https://doi.org/10.1016/j.ajpath.2021.04.010
Abstract
No abstract availableFunding Information
- FAEPA
This publication has 97 references indexed in Scilit:
- Mitogen-activated protein kinases in innate immunityNature Reviews Immunology, 2013
- Thrombosis as an intravascular effector of innate immunityNature Reviews Immunology, 2012
- The emerging role of ACE2 in physiology and diseaseThe Journal of Pathology, 2007
- The interactions between inflammation and coagulationBritish Journal of Haematology, 2005
- Spatial and temporal dynamics of the endotheliumJournal of Thrombosis and Haemostasis, 2005
- Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indicationsKidney International, 2005
- Tissue renin-angiotensin system and end-organ damage.Journal of Molecular Medicine, 2002
- MAP Kinases in the Immune ResponseAnnual Review of Immunology, 2002
- A Human Homolog of Angiotensin-converting EnzymeOnline Journal of Public Health Informatics, 2000
- Interleukin-6 Family of Cytokines Mediate Angiotensin II-induced Cardiac Hypertrophy in Rodent CardiomyocytesOnline Journal of Public Health Informatics, 2000